News
Madam Therapeutics has been awarded a grant from the Netherlands Antibiotic Development Platform (NADP)
Madam Therapeutics announced that it is one of the four companies in the Netherlands that have been awarded a novel grant from the Netherlands Antibiotic Development Platform (NADP).
The Netherlands organise Global Conference against antibiotic resistance
Together with the World Health Organization (WHO), The Netherlands will organise a global conference in April 2019 about the fight against antibiotic resistance.
Madam Therapeutics closes first financing round to develop novel antibiotics against drug resistant bacteria
Madam Therapeutics, a privately-held biotech company that is developing a novel class of antibiotics inspired by the defense mechanisms of the human body, today announced the closing of its first financing round of 1,1M EUR.
Launch of Global AMR R&D Hub in Geneve
On the 22nd of May, alongside the annual World Health Assembly in Geneva the Global Antimicrobial Resistance and Development Hub (Global AMR R&D Hub) was launched.
Millions earmarked to boost research into new life-saving products to address the global rise of drug-resistant bacteria
The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.
Company in the spotlight: Avivia B.V.
NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column “Company in the spotlight” issue. In our second edition, we speak with Dr. Hans Platteeuw, founder and CEO of Avivia B.V., a Nijmegen based company that supports pharmaceutical development for new and existing drugs including drug repurposing and reformulation.